On the contrary, both niraparib and talazoparib, two PARP inhibitors with higher PARP-trapping potency than olaparib, dose-dependently inhibited the viability of the SW480 and SW1116 cancer cells in the presence of 0.75 μM alkannin (Figures 3E,F, Supplementary Figures S3E,F). The gene discussed is PARP1; the disease is cancer.